Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics
ALNA Price/Volume Stats
| Current price | $0.08 | 52-week high | $1.17 |
| Prev. close | $0.07 | 52-week low | $0.06 |
| Day low | $0.06 | Volume | 276,971,600 |
| Day high | $0.15 | Avg. volume | 15,688,501 |
| 50-day MA | $0.14 | Dividend yield | N/A |
| 200-day MA | $0.30 | Market Cap | 9.16M |
ALNA Stock Price Chart Interactive Chart >
Allena Pharmaceuticals, Inc. (ALNA) Company Bio
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.
Latest ALNA News From Around the Web
Below are the latest news stories about ALLENA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNA as an investment opportunity.
Allena Pharma Needs To Raise Capital To Continue As A Going ConcernAllena Pharmaceuticals Inc (NASDAQ: ALNA) says it lacks the financial resources to conduct studies for ALLN-346 for hyperuricemia and gout in the setting of advanced chronic kidney disease. The company continues to evaluate the data from cohorts A and B of Study 202 and the long-term viability of the ALLN-346 clinical program. In light of the clinical data observed to date, in particular the data from Study 201, which demonstrated a potential GI-based mechanism of action, it is possible that the |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney DiseaseNEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disea |
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitNEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to ef |
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitNEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of in |
ALNA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -92.38% |
| 5-year | -98.13% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -53.71% |
| 2020 | -53.11% |
| 2019 | -49.91% |
Loading social stream, please wait...